News Releases

News Releases

Motif Bio plc (AIM/Nasdaq: MTFB) announces that its subsidiary Motif BioSciences Inc., has reached agreement with its former clinical research organisation to settle all obligations without further payment.  This will result in the reversal of a previously recognised expense and the reduction of
November 11, 2019
             RNS Number : 3464P   Motif Bio PLC   10 October 2019         Motif Bio plc (" Motif Bio ", or "the Company")   Motif Bio confirms receipt of FDA meeting minutes   Motif Bio plc (AIM/NASDAQ: MTFB) today announced that the Company has received the official minutes of the Type B meeting
October 10, 2019
             RNS Number : 5912O   Motif Bio PLC   03 October 2019           Motif Bio plc (" Motif Bio ", or "the Company")   Change of Adviser   Motif Bio plc (AIM/NASDAQ: MTFB) is pleased to announce the appointment of SP Angel Corporate Finance LLP as nominated adviser and sole corporate broker
October 03, 2019
NEW YORK , Sept. 02, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB) ("Motif Bio" or the "Company"), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that its lender, Hercules Capital, Inc. (“Hercules”), has agreed to amend the Company’s
September 02, 2019
NEW YORK , Aug. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will be utilising NIAID’s 1 suite of preclinical services through JMI Laboratories to evaluate
August 19, 2019
NEW YORK , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that its Lender, Hercules Capital, Inc. , has agreed to amend the Company’s loan and security agreement such that
August 01, 2019
NEW YORK , July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration ( FDA ) has granted the Company’s request for a Type B meeting related to
July 26, 2019
NEW YORK , July 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s trading
July 26, 2019
NEW YORK , July 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that it has received a deficiency notice from Nasdaq indicating that, based upon a review of Motif Bio’s Market
July 19, 2019
NEW YORK , June 24, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today reported that new iclaprim data were presented at the American Society For Microbiology (ASM) Microbe 2019 meeting held in
June 24, 2019
NEW YORK , May 31, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Annual General Meeting held earlier today, all but one of the resolutions proposed were duly passed by the
May 31, 2019
NEW YORK , May 22, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier today the Company provided the following review of key aspects of its business and
May 22, 2019
NEW YORK , May 21, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that three iclaprim abstracts have been accepted for presentation at the upcoming American Society For Microbiology
May 21, 2019
NEW YORK , May 03, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, confirms that the Company met with the U.S. Food & Drug Administration ( FDA ) on May 3, 2019 as expected.
May 03, 2019
Evaluation of Iclaprim in Combination with LMS-611 for Cystic Fibrosis Lung Infections NEW YORK , May 01, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/Nasdaq: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company has signed
May 01, 2019
NEW YORK , April 26, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc ("Motif Bio" or the "Company") (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that its notice of its Annual General Meeting (AGM) have been posted to
April 26, 2019
NEW YORK , April 16, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that new iclaprim data are being presented at the 28 th European Congress of Clinical Microbiology and Infectious
April 16, 2019
NEW YORK , April 15, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced financial results for the year ended December 31, 2018 . Dr. Graham Lumsden , Chief Executive Officer, said:
April 15, 2019
NEW YORK, April 04, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that four iclaprim abstracts have been accepted for presentation at the upcoming 28th European Congress of Clinical
April 04, 2019
Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the U.S. Food & Drug Administration (FDA) has granted the Company’s request for a Type A meeting to discuss the points raised in the Complete Response
March 20, 2019
NEW YORK , Feb. 19, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced that the Company will hold a conference call on Tuesday, February 19, 2019 at 8:30 AM ET / 1:30 PM GMT / 2:30 PM
February 19, 2019
NEW YORK , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Motif Bio plc (AIM/NASDAQ: MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announced today that the Company has received a Complete Response Letter (CRL) from the U.S.
February 14, 2019